Oxygen Biotherapeutics to Present at Two Upcoming Healthcare Investor Conferences Print
Business Wire
Tuesday, 07 January 2014 03:06
Biotech Showcase™ 2014 on January 15th
Jan. 7, 2014 13:00 UTC

Oxygen Biotherapeutics to Present at Two Upcoming Healthcare Investor Conferences

OneMedForum San Francisco 2014 on January 13th

Biotech Showcase™ 2014 on January 15th

OneMedForum 2014 Biotech Showcase 2014

MORRISVILLE, N.C.--(BUSINESS WIRE)-- Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that it is scheduled to present at two upcoming healthcare investor conferences in San Francisco.

Oxygen Biotherapeutics’ Chief Executive Officer, John Kelley will deliver a Company presentation at the OneMedForum on Monday, January 13th at 11:30am and the Biotech Showcase™ 2014 Conference on Wednesday, January 15th at 11:30am. Mr. Kelley will provide an update on the business operations, including the acquisition of certain assets of Phyxius Pharma Inc. and the development and near-term commercialization of levosimendan to prevent and treat cardiac surgery patients at risk for developing low cardiac output syndrome (LCOS). To arrange a one-on-one meeting with management, please contact Robert Haag at oxbt@irthcommunications.com or 1-866-976-IRTH.

The Seventh Annual OneMedForum will feature over 80 growth companies and 1,200 investors. The event focuses on the areas of greatest investment opportunity in therapeutics, devices, diagnostics and health information and will also showcase the most promising microcap public companies and high growth private (pre-IPO) companies. It has established a quality brand that consistently assembles leading investors and

executives. The event will be held January 13-15, 2014 at the Westin San Francisco Market Street, California.

Biotech Showcase™ is an investor and

Error. Page cannot be displayed. Please contact your service provider for more details. (17)

partnering conference devoted to providing private and
public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry’s largest annual healthcare investor conferences. Now in its sixth year, Biotech Showcase is expected to attract upwards of 1,700 attendees. The event will take place January 13-15, 2014 at the Parc 55 Wyndham San Francisco Union Square Hotel, California.

About Oxygen Biotherapeutics

Oxygen Biotherapeutics, Inc. is developing medical products for the acute care market. The company recently acquired the North American rights to develop and commercialize levosimendan. The United States Food and Drug Administration (FDA) has granted Fast Track status for levosimendan for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome (LCOS). In addition, the FDA has agreed to a Phase 3 protocol design under Special Protocol Assessment (SPA), and provided guidance that a single successful trial will be sufficient to support approval of levosimendan in this indication. The company also has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte® that is currently in clinical and preclinical studies for intravenous delivery for indications such as traumatic brain injury, decompression sickness and stroke.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company’s judgment as of the date of this release. The forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to matters beyond the company's control that could lead to delays in the clinical study, delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in the company’s filings with the Securities and Exchange Commission, including in its quarterly report on Form 10-Q filed on September 17, 2013, and annual report on Form 10-K filed on June 26, 2013, as well as its other filings with the SEC. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. Statements in this press release regarding management’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Contacts

IRTH Communications
Robert Haag, 1-866-976-4784
oxbt@irthcommunications.com


Source: Oxygen Biotherapeutics, Inc.




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
  BMR:1